BEAM THERAPEUTICS
Live / Applied — Second extension granted (statement of use) (as of 17 Nov 2025)
What this means for you
Not registered yet, but its 04 Oct 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98209503
- Mark type
- Stylized text
- Filed
- 04 Oct 2023
- Published for opposition
- 08 Oct 2024
- Attorney of record
- John V. Hobgood, Esquire
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations based on base editing, base modification, nucleobase editing, nucleobase modification, nucleic acid editing, gene editing, gene modification, gene modulation, gene reprogramming, gene therapy, genome editing, genome modification, cell therapy, cellular modification, tissue modification, and organ modification for use in human therapeutics for the treatment of Sickle Cell Disease, Beta Thalassemia, Alpha-1 Antitrypsin Deficiency, Glycogen Storage Disease Ia, Cancer, T-Cell Cancer, T-Cell Acute Lymphoblastic Leukemia, CD7 positive Acute Myeloid Leukemia, and Stargardt Disease
Owner
- Beam Therapeutics Inc., Cambridge, MA, US
- Beam Therapeutics Inc., Cambridge, MA, US
Prosecution history
- 18 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 Nov 2025 — SOU EXTENSION 2 GRANTED
- 17 Nov 2025 — SOU EXTENSION 2 FILED
- 17 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 15 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 May 2025 — SOU EXTENSION 1 GRANTED
- 14 May 2025 — SOU EXTENSION 1 FILED
- 14 May 2025 — SOU TEAS EXTENSION RECEIVED
- 19 Nov 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 08 Oct 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 08 Oct 2024 — PUBLISHED FOR OPPOSITION
- 18 Sept 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 04 Sept 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 22 Aug 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 22 Aug 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE